New MRI study to see if triple inhaler opens lungs better in COPD

NCT ID NCT07192016

Recruiting now Disease control Sponsor: Western University, Canada Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study will test a once-daily triple inhaler (Trelegy) in 60 adults with moderate-to-severe COPD. Participants will take the inhaler for 12 weeks (with an optional 48-week extension) and undergo special 129-Xenon MRI scans to see how well air moves through their lungs. The goal is to compare lung function improvements between people at low risk and high risk of flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fluticasone furoate/umeclidinium/vilanterol (Trelegy) triple inhaler
What this could lead to: If successful, this study could show that a once-daily triple inhaler improves lung ventilation in COPD patients, especially those at high risk of flare-ups.
What could go wrong: This is a small, early-phase 4 study with only 60 participants, so results may not apply to all COPD patients. The main goal is to measure lung changes on MRI, not to prove long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Locations

Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre
RECRUITING

London, Ontario, N6A 5B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.